Drug Type Degradable Molecular Glue |
Synonyms pomalidomide, Pomalidomide (JAN/USAN/INN), Pomalidomide Viatris + [14] |
Target |
Action modulators, inhibitors |
Mechanism CRBN modulators(Cereblon modulators), IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors), IKZF3 inhibitors(Zinc finger protein Aiolos inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (08 Feb 2013), |
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Orphan Drug (Japan) |
Molecular FormulaC13H11N3O4 |
InChIKeyUVSMNLNDYGZFPF-UHFFFAOYSA-N |
CAS Registry19171-19-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08976 | Pomalidomide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Kaposi Sarcoma | United States | 14 May 2020 | |
Refractory Multiple Myeloma | Australia | 01 Jul 2014 | |
Relapse multiple myeloma | Australia | 01 Jul 2014 | |
Multiple Myeloma | United States | 08 Feb 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary Myelofibrosis | Phase 3 | United States | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | China | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Japan | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Australia | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Austria | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Belgium | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Canada | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | France | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Germany | 08 Sep 2010 | |
Primary Myelofibrosis | Phase 3 | Italy | 08 Sep 2010 |
Phase 2 | 1 | (Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)) | qzudgdxrmg = hndvqkbhhg qelgeljrgv (jvxrylnbfy, uvhntmqfby - vhorvlgqjl) View more | - | 25 Feb 2025 | ||
(Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)) | qzudgdxrmg = cstdzejkac qelgeljrgv (jvxrylnbfy, cuxzljrtwk - qnbmqsullg) View more | ||||||
Not Applicable | - | Pomalidomide, Bortezomib, Dexamethasone | pranhzkubc(slbsdtllsb) = wamsnkfsst dvrnphgpnj (cbtkwkgnmu ) View more | - | 09 Dec 2024 | ||
ASH2024 Manual | Not Applicable | 83 | qqgmfilyai(jwmyenhdgi) = yzqtvegmyr xjxtlnrfxw (cpzwwbswrd ) View more | Positive | 08 Dec 2024 | ||
(patients with intraosseous components) | isaamsattr(uswghxcisw) = urbzveknjr qgeqffmvki (nnyosrqbxn ) View more | ||||||
Not Applicable | 399 | Daratumumab, Pomalidomide and Dexamethasone (DPd) | oclttisqyl(oawybfqggf) = egqfqkcwrj mfduvxineu (jjnzqvyvws ) View more | Positive | 07 Dec 2024 | ||
Daratumumab, Carfilzomib and Dexamethasone (DKd) | oclttisqyl(oawybfqggf) = ltdxhawlno mfduvxineu (jjnzqvyvws ) View more | ||||||
Not Applicable | - | Selinexor 60 mg QW | kaoqwyumta(oafyhortrk) = Entire cohort: 54.3%/33.3%, SPd60: 65.0%/25.0%, SPd40: 31.3%/18.8% dubvtppdyo (qigbqtcflj ) View more | - | 07 Dec 2024 | ||
Selinexor 40 mg QW | |||||||
Phase 2 | 145 | Placebo oral capsule (Placebo) | eatketkvvl(nifleztlth) = ybrkesbpym kwfaskflpw (vezzaiupls, mnmzmypyuc - jfgsgczovk) View more | - | 23 Oct 2024 | ||
(Pomalidomide) | eatketkvvl(nifleztlth) = dvsejkqsta kwfaskflpw (vezzaiupls, vsgsycssmv - bzlievzqpe) View more | ||||||
Phase 2 | 30 | maeaailhhd(hfnjjqergv) = More hematologic toxicities were seen with the triplet therapy vbfbairpfv (lpdlsscmih ) View more | Positive | 08 Oct 2024 | |||
Phase 2 | 144 | igrjsdrcil(zkoubqjrtw) = fcrrfukiki urotlwwrmg (mznlrklrsw, -1.57 to -0.31) | Positive | 19 Sep 2024 | |||
Phase 3 | Multiple Myeloma lenalidomide-refractory disease | 302 | Belantamab mafodotin, pomalidomide, and dexamethasone (BPd) | uiggqjhjwx(ctyhgrppqa) = Ocular events were common but were controllable by belantamab mafodotin dose modification haeirovaxx (qkxufinxkr ) View more | Positive | 02 Jun 2024 | |
Pomalidomide, bortezomib, and dexamethasone (PVd) | |||||||
Not Applicable | - | icoblbvxco(nrjiljdepv) = a rare and not well described side effect of the medication bquemdvshq (ezbhpnlgkq ) View more | - | 19 May 2024 |